Eledon Pharmaceuticals (ELDN) Competitors $3.85 -0.03 (-0.77%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ELDN vs. NEOS, MLND, STOK, OCS, TRML, IMNM, CDXC, GHRS, IGMS, and ABVXShould you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Neos Therapeutics (NEOS), Millendo Therapeutics (MLND), Stoke Therapeutics (STOK), Oculis (OCS), Tourmaline Bio (TRML), Immunome (IMNM), ChromaDex (CDXC), GH Research (GHRS), IGM Biosciences (IGMS), and ABIVAX Société Anonyme (ABVX). These companies are all part of the "medical" sector. Eledon Pharmaceuticals vs. Neos Therapeutics Millendo Therapeutics Stoke Therapeutics Oculis Tourmaline Bio Immunome ChromaDex GH Research IGM Biosciences ABIVAX Société Anonyme Neos Therapeutics (NASDAQ:NEOS) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment. Does the media prefer NEOS or ELDN? In the previous week, Eledon Pharmaceuticals had 13 more articles in the media than Neos Therapeutics. MarketBeat recorded 13 mentions for Eledon Pharmaceuticals and 0 mentions for Neos Therapeutics. Eledon Pharmaceuticals' average media sentiment score of 0.54 beat Neos Therapeutics' score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Neos Therapeutics Neutral Eledon Pharmaceuticals Positive Does the MarketBeat Community prefer NEOS or ELDN? Neos Therapeutics received 473 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 72.97% of users gave Eledon Pharmaceuticals an outperform vote while only 63.78% of users gave Neos Therapeutics an outperform vote. CompanyUnderperformOutperformNeos TherapeuticsOutperform Votes50063.78% Underperform Votes28436.22% Eledon PharmaceuticalsOutperform Votes2772.97% Underperform Votes1027.03% Do insiders & institutionals have more ownership in NEOS or ELDN? 33.1% of Neos Therapeutics shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 3.8% of Neos Therapeutics shares are held by insiders. Comparatively, 11.7% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, NEOS or ELDN? Neos Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Do analysts recommend NEOS or ELDN? Eledon Pharmaceuticals has a consensus target price of $16.00, indicating a potential upside of 315.58%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Neos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, NEOS or ELDN? Neos Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Neos Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeos Therapeutics$64.65M0.89-$16.90M-$0.34-3.38Eledon PharmaceuticalsN/AN/A-$116.54M-$2.01-1.92 Is NEOS or ELDN more profitable? Eledon Pharmaceuticals has a net margin of 0.00% compared to Neos Therapeutics' net margin of -38.35%. Neos Therapeutics' return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Neos Therapeutics-38.35% N/A -28.46% Eledon Pharmaceuticals N/A -189.99%-28.17% SummaryEledon Pharmaceuticals beats Neos Therapeutics on 11 of the 17 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELDN vs. The Competition Export to ExcelMetricEledon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$152.68M$6.45B$5.04B$8.81BDividend YieldN/A8.11%5.16%4.07%P/E Ratio-1.9210.78130.5317.82Price / SalesN/A243.701,183.8674.55Price / CashN/A22.1633.6132.53Price / Book12.835.474.684.68Net Income-$116.54M$153.61M$119.23M$226.08M7 Day Performance-6.78%-2.00%-1.83%-1.04%1 Month Performance27.06%-7.46%-3.61%1.04%1 Year Performance220.83%31.82%31.74%26.28% Eledon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELDNEledon Pharmaceuticals2.9395 of 5 stars$3.85-0.8%$16.00+315.6%+210.5%$153.86MN/A-1.9210Analyst ForecastAnalyst RevisionNEOSNeos TherapeuticsN/A$1.15flatN/A+0.0%$57.22M$64.65M-3.38213Analyst ForecastHigh Trading VolumeMLNDMillendo TherapeuticsN/A$0.90+3.5%N/A-77.1%$17.11MN/A0.0012Gap UpSTOKStoke Therapeutics3.8396 of 5 stars$11.31-2.6%$20.83+84.2%+171.2%$614.95M$8.78M0.00100OCSOculis2.6709 of 5 stars$14.91-0.7%$29.20+95.8%+55.3%$608.37M$980,000.00-7.732TRMLTourmaline Bio1.8572 of 5 stars$24.00+2.1%$65.00+170.8%+36.0%$602.60MN/A0.0044IMNMImmunome1.5384 of 5 stars$9.33-0.6%$28.83+209.0%+19.8%$586.09M$14.02M0.0040Analyst RevisionCDXCChromaDex3.8229 of 5 stars$7.50-0.3%$8.00+6.7%+417.2%$572.85M$83.57M735.74106Analyst DowngradeGHRSGH Research1.3894 of 5 stars$10.95+13.9%$35.67+225.7%+77.2%$569.71MN/A-13.8610Analyst ForecastIGMSIGM Biosciences4.693 of 5 stars$9.77+2.4%$16.13+65.1%+63.3%$567.29M$2.13M0.00190ABVXABIVAX Société Anonyme2.9963 of 5 stars$8.86-0.6%$39.80+349.2%-19.6%$560.79MN/A0.0061 Related Companies and Tools Related Companies NEOS Competitors MLND Competitors STOK Competitors OCS Competitors TRML Competitors IMNM Competitors CDXC Competitors GHRS Competitors IGMS Competitors ABVX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELDN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
